| Identification | Back Directory | [Name]
(9H-fluoren-9-yl)Methyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)aMino)-1-Methoxy-2-Methyl-3-oxopropyl)pyrrolidin-1-yl)-3-Methoxy-5-Methyl-1-oxoheptan-4-yl)(Methyl)aMino)-3-Methyl-1-oxobutan-2-yl)aMino)-3-Met | [CAS]
474645-26-6 | [Synonyms]
Fmoc-MMAE
Fmoc-DL-N(Me)Val-DL-Val-Unk
((S)-1 - ((S)-1 - (((3R,4S,5S)-1 - ((S)-2 - ((1R,2
(9H-fluoren-9-yl)Methyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)aMino)-1-Methoxy-2-Methyl-3-oxopropyl)pyrrolidin-1-yl)-3-Methoxy-5-Methyl-1-oxoheptan-4-yl)(Methyl)aMino)-3-Methyl-1-oxobutan-2-yl)aMino)-3-Met
L-Valinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- (9CI)
(9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate | [Molecular Formula]
C54H77N5O9 | [MDL Number]
MFCD28386986 | [MOL File]
474645-26-6.mol | [Molecular Weight]
940.22 |
| Chemical Properties | Back Directory | [Boiling point ]
1036.4±65.0 °C(Predicted) | [density ]
1.148±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, stored under nitrogen ,unstable in solution, ready to use. | [solubility ]
DMSO : ≥ 45 mg/mL (47.86 mM) | [form ]
Solid | [pka]
13.66±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC[1]. | [IC 50]
Auristatin | [storage]
4°C, stored under nitrogen ,unstable in solution, ready to use. | [References]
[1] Pan D, et al. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer. Cancer Med. 2020;9(24):9529-9540. DOI:10.1002/cam4.3554 |
|
| Company Name: |
csynbio
|
| Tel: |
15051477682 |
| Website: |
m.is0513.com/showsupplierproductslist1949820/0.htm |
|